Golden Green’s AbbVie ABBV Stock Holding History

Golden Green’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1,992	Closed	-$213K	–	167
2020 Q4	$213K	Buy	+1,992	New	+$191K	0.2%	104

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Golden Green's ABBV Position: Q1 2021 in Review

Golden Green sold out of AbbVie (ABBV) in Q1 2021, closing a stake of 1,992 shares — an estimated $213K sold.

Golden Green first reported a position in ABBV in Q4 2020 and held it in 1 quarter. The position peaked at $213K in Q4 2020. 2,615 funds tracked by Wall St. Rank hold ABBV as of Q1 2021.

Golden Green reported no remaining AbbVie position as of Q1 2021 after selling out during the quarter.
Golden Green sold 1,992 AbbVie shares in Q1 2021, an estimated $213K.
Golden Green first reported a position in AbbVie in Q4 2020 and held it in 1 quarter.
Golden Green's AbbVie position peaked at $213K in Q4 2020.
2,615 funds tracked by Wall St. Rank held AbbVie as of Q1 2021.

Based on Golden Green's 13F filing for Q1 2021, filed 13 Apr 2021.